Protalix BioTherapeutics Reports Strong Revenue Growth in 2025

Protalix Biotherapeutics ( (PLX) ) has released its Q3 earnings. Here is a breakdown of the information Protalix Biotherapeutics presented to its investors.

Protalix BioTherapeutics, Inc. is a biopharmaceutical company specializing in the development and commercialization of recombinant therapeutic proteins using its proprietary plant cell-based expression system, ProCellEx. The company has achieved a notable milestone as the first to gain FDA approval for a protein produced through this unique system.

In its third quarter of 2025, Protalix reported total revenues of $43.6 million for the first nine months, marking a 24% increase compared to the same period in 2024. However, the third-quarter revenue saw a slight decrease of 1% year-over-year, totaling $17.9 million. The company attributes its revenue to sales of its enzyme replacement therapies to partners like Chiesi, Pfizer, and Fiocruz in Brazil.

Key financial highlights include a net income of $2.4 million for the third quarter, a decrease from $3.2 million in the same period last year. The company also reported an increase in research and development expenses, primarily due to preparations for the phase 2 clinical trial of PRX-115, a promising candidate for treating uncontrolled gout. Additionally, Protalix’s selling, general, and administrative expenses rose by 12% in the third quarter.

Protalix is optimistic about its future, with plans to initiate a phase 2 clinical trial for PRX-115 later this year. The company remains focused on advancing its pipeline, which includes other promising candidates like PRX-119. With $29.4 million in cash and equivalents, Protalix is well-positioned to meet its capital needs for at least the next 12 months.

Looking ahead, Protalix’s management is committed to leveraging its innovative ProCellEx platform to develop and commercialize new therapies, while navigating regulatory challenges and expanding its market presence globally.